These pro-inflammatory cytokines contribute to hepatic steatosis by activating SOCS, which not only interfere with hepatic insulin signaling as described above, but also inhibit STAT signaling, enhancing expression of the sterol regulatory element binding protein 1 (SREBP-1c) [95]. The gene discussed is SREBF1; the disease is fatty liver disease.